Neuberger Berman Group LLC lowered its holdings in Pfizer Inc. (NYSE:PFE) by 8.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 7,309,579 shares of the biopharmaceutical company’s stock after selling 695,922 shares during the quarter. Neuberger Berman Group LLC owned 0.13% of Pfizer worth $238,953,000 as of its most recent SEC filing.
Several other large investors have also added to or reduced their stakes in the company. Public Employees Retirement Association of Colorado grew its position in shares of Pfizer by 5.6% in the first quarter. Public Employees Retirement Association of Colorado now owns 1,047,712 shares of the biopharmaceutical company’s stock valued at $34,197,000 after purchasing an additional 55,805 shares during the period. Victory Capital Management Inc. lifted its stake in shares of Pfizer by 0.9% in the first quarter. Victory Capital Management Inc. now owns 4,745,649 shares of the biopharmaceutical company’s stock worth $154,898,000 after buying an additional 42,610 shares in the last quarter. BRYN MAWR TRUST Co lifted its stake in shares of Pfizer by 0.6% in the first quarter. BRYN MAWR TRUST Co now owns 220,066 shares of the biopharmaceutical company’s stock worth $7,183,000 after buying an additional 1,352 shares in the last quarter. Cambridge Investment Research Advisors Inc. raised its stake in Pfizer by 21.8% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 1,308,348 shares of the biopharmaceutical company’s stock worth $42,704,000 after purchasing an additional 234,179 shares during the period. Finally, Aigen Investment Management LP purchased a new position in Pfizer during the first quarter worth about $385,000. Hedge funds and other institutional investors own 69.08% of the company’s stock.
A number of brokerages have weighed in on PFE. Morgan Stanley lifted their price target on shares of Pfizer from $36.00 to $42.00 and gave the company an “equal weight” rating in a research report on Thursday, July 30th. Piper Sandler lifted their price target on shares of Pfizer from $18.50 to $24.00 in a research report on Friday, June 26th. UBS Group lifted their price objective on shares of Pfizer from $37.00 to $39.00 and gave the company a “neutral” rating in a report on Wednesday, July 29th. JPMorgan Chase & Co. dropped their price objective on shares of Pfizer from $37.00 to $36.00 and set a “neutral” rating for the company in a report on Monday, June 1st. Finally, Royal Bank of Canada set a $43.00 price objective on shares of Pfizer and gave the company a “buy” rating in a report on Wednesday, September 9th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $39.61.
In other Pfizer news, Director Ronald E. Blaylock acquired 13,000 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were purchased at an average cost of $38.55 per share, with a total value of $501,150.00. Following the purchase, the director now owns 4,000 shares in the company, valued at $154,200. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.08% of the stock is currently owned by corporate insiders.
Shares of NYSE:PFE traded down $0.02 on Wednesday, reaching $36.94. 764,366 shares of the company were exchanged, compared to its average volume of 29,486,596. The company has a current ratio of 1.42, a quick ratio of 1.16 and a debt-to-equity ratio of 0.78. Pfizer Inc. has a 1-year low of $27.88 and a 1-year high of $40.97. The firm has a market cap of $205.38 billion, a price-to-earnings ratio of 14.69, a price-to-earnings-growth ratio of 2.91 and a beta of 0.67. The company has a 50-day moving average of $37.79 and a 200-day moving average of $35.69.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, July 28th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.64 by $0.14. Pfizer had a net margin of 28.80% and a return on equity of 25.11%. The business had revenue of $11.80 billion for the quarter, compared to analysts’ expectations of $11.55 billion. During the same period in the prior year, the company posted $0.80 EPS. The business’s revenue for the quarter was down 11.0% on a year-over-year basis. As a group, analysts forecast that Pfizer Inc. will post 2.89 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 1st. Investors of record on Friday, July 31st were paid a $0.38 dividend. The ex-dividend date was Thursday, July 30th. This represents a $1.52 dividend on an annualized basis and a yield of 4.11%. Pfizer’s payout ratio is 51.53%.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
See Also: Understanding Stock Ratings
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.